Myriad Genetics (MYGN) Inventory Average (2011 - 2026)

Myriad Genetics has disclosed Inventory Average across 16 years of filings, most recently posting $29.2 million for Q1 2026.

• In Q1 2026, Inventory Average rose 4.84% year-over-year to $29.2 million; the TTM figure through Mar 2026 stood at $29.2 million (up 4.84% YoY), while the FY2025 annual figure was $29.0 million, up 17.37% from the prior year.
• Inventory Average retreated to $29.2 million in Q1 2026, from $31.1 million in the prior quarter.
• Over the last five years, Inventory Average for MYGN reached as high as $31.1 million in Q4 2025 and fell as low as $15.4 million in Q1 2022.
• The 5-year median for Inventory Average is $23.8 million (2023), against an average of $24.0 million.
• Annual changes were most pronounced in 2022 — Inventory Average slumped 40.23% — and 2023, when it surged 42.9%.
• A 5-year view of Inventory Average shows it stood at $19.8 million in 2022, then grew by 18.64% to $23.6 million in 2023, then grew by 14.01% to $26.8 million in 2024, then rose by 15.83% to $31.1 million in 2025, then declined by 5.95% to $29.2 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $29.2 million, $31.1 million, and $30.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.